These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 8314360

  • 21. [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits].
    Zhou J, Jiang XH, He L, Li CR, Yang JY.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):145-7. PubMed ID: 16468665
    [Abstract] [Full Text] [Related]

  • 22. A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells.
    Yamauchi T, Ueda T.
    Biochem Pharmacol; 2005 Jun 15; 69(12):1795-803. PubMed ID: 15935150
    [Abstract] [Full Text] [Related]

  • 23. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
    Bassan R, Chiodini B, Zucchetti M, Lerede T, Cornelli PE, Cortelazzo S, Barbui T.
    Haematologica; 1998 Jan 15; 83(1):27-33. PubMed ID: 9542320
    [Abstract] [Full Text] [Related]

  • 24. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL, Tseng YL.
    Cancer; 2001 May 01; 91(9):1826-33. PubMed ID: 11335910
    [Abstract] [Full Text] [Related]

  • 25. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 26. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Sep 01; 82(6):664-7. PubMed ID: 9499665
    [Abstract] [Full Text] [Related]

  • 27. [Skin toxicity associated with bolus infusion of low-dose cytarabine].
    Takeuchi M, Tanizawa A, Fukumoto Y, Kikawa Y, Mayumi M.
    Rinsho Ketsueki; 2001 Mar 01; 42(3):216-7. PubMed ID: 11345785
    [Abstract] [Full Text] [Related]

  • 28. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam.
    Kim S, Khatibi S, Howell SB, McCully C, Balis FM, Poplack DG.
    Cancer Res; 1993 Apr 01; 53(7):1596-8. PubMed ID: 8453629
    [Abstract] [Full Text] [Related]

  • 29. [Cytarabine-induced pericarditis].
    Yamada T, Tsurumi H, Hara T, Sawada M, Oyama M, Moriwaki H.
    Rinsho Ketsueki; 1998 Nov 01; 39(11):1115-20. PubMed ID: 9866424
    [Abstract] [Full Text] [Related]

  • 30. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 01; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 31. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Nov 01; 82(5 Suppl):19-22. PubMed ID: 9402749
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C.
    Cheon EP, Han HK.
    Acta Pharmacol Sin; 2007 Feb 01; 28(2):268-72. PubMed ID: 17241530
    [Abstract] [Full Text] [Related]

  • 33. [Experimental study of cord blood plasma enhancing the anti-leukemia effect of Ara-C].
    Zhang X, Chen Y, Wang X.
    Zhonghua Xue Ye Xue Za Zhi; 1999 May 01; 20(5):229-31. PubMed ID: 11601208
    [Abstract] [Full Text] [Related]

  • 34. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 01; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 35. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 36. Effects of high-dose cytarabine.
    Hande KR, Stein RS, McDonough DA, Greco FA, Wolff SN.
    Clin Pharmacol Ther; 1982 May 15; 31(5):669-74. PubMed ID: 7075116
    [Abstract] [Full Text] [Related]

  • 37. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
    Higa GM, Gockerman JP, Hunt AL, Jones MR, Horne BJ.
    Cancer; 1991 Oct 15; 68(8):1691-3. PubMed ID: 1913509
    [Abstract] [Full Text] [Related]

  • 38. Spiral assembly of amphiphilic cytarabine prodrug assisted by probe sonication: Enhanced therapy index for leukemia.
    Liu J, Ma N, Zhao D, Li Z, Luan Y.
    Colloids Surf B Biointerfaces; 2015 Dec 01; 136():918-27. PubMed ID: 26551869
    [Abstract] [Full Text] [Related]

  • 39. Acute cerebellar dysfunction with high-dose Ara-C therapy.
    Lazarus HM.
    Cancer; 1984 Jun 15; 53(12):17A. PubMed ID: 6722718
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic studies on ara-C. With special emphasis on the cellular pharmacokinetics.
    Liliemark J.
    Scand J Haematol Suppl; 1986 Jun 15; 44():41-50. PubMed ID: 3457438
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.